Xilio Therapeutics (NASDAQ:XLO) Shares Down 0.5% – Here’s Why

Xilio Therapeutics, Inc. (NASDAQ:XLO) fell 0.5% during trading on Friday . The stock traded as low as $0.6550 and last traded at $0.6619. 218,489 shares were traded during trading, a decline of 57% from the average session volume of 504,235 shares. The stock had previously closed at $0.6653.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Xilio Therapeutics in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $2.00.

Xilio Therapeutics Stock Performance

The firm has a market cap of $34.75 million, a price-to-earnings ratio of -1.02 and a beta of -0.07. The business has a fifty day simple moving average of $0.74 and a 200-day simple moving average of $0.73.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). Xilio Therapeutics had a negative return on equity of 679.66% and a negative net margin of 183.90%.The firm had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.64 million. On average, equities analysts anticipate that Xilio Therapeutics, Inc. will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. ADAR1 Capital Management LLC purchased a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 40,000 shares of the company’s stock, valued at approximately $29,000. ADAR1 Capital Management LLC owned about 0.08% of Xilio Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.